Experimental cancer combo aims to supercharge immune attack on tumors
NCT ID NCT03252938
First seen Jan 23, 2026 · Last updated Jun 23, 2026 · Updated 20 times
Summary
This early-phase trial tests an experimental drug called IMP321, which activates immune cells, in combination with other cancer treatments like chemotherapy or immunotherapy. The study includes 83 people with advanced solid tumors, including lung and bladder cancers. The main goal is to see if giving IMP321 in new ways—such as directly into tumors or the abdomen—is safe and feasible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMORS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Agaplesion Markus Krankenhaus Frankfurter Diakonie Kliniken gGmbH
Frankfurt, 60431, Germany
-
Helios Dr. Horst Schmidt Klinikum Wiesbaden
Wiesbaden, 65199, Germany
-
Helios Klinikum Bad Saarow
Bad Saarow, 15526, Germany
-
Hämatologisch Onkologische Praxis Eppendorf (HOPE)
Hamburg, 20249, Germany
-
Kliniken der Stadt Köln gGmbH, Studienzentrum der Lungenklinik, Krankenhaus Merheim
Cologne, 51109, Germany
-
Krankenhaus Nordwest
Frankfurt, 60488, Germany
-
Marienhospital Herne, Klinik der Ruhr Universität Bochum, Klinik für Urologie
Herne, 44625, Germany
-
Universität Gießen und Marburg GmbH
Giessen, 35392, Germany
-
Universitätsklinikum Essen
Essen, 45147, Germany
-
Universitätsklinikum Tübingen
Tübingen, 72076, Germany
-
Universitätsklinikum Ulm, Early Clinical Trials Unit (ECTU)
Ulm, 89081, Germany
-
Universitätsmedizin der Johannes Gutenberg-Universität Mainz
Mainz, 55131, Germany
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
IMP321 (eftilagimod alfa) and avelumab
What this could lead to
If successful, this could point toward new ways to boost the immune system to fight advanced solid tumors.
What could go wrong
This is an early Phase 1 trial with a small number of participants, so it is too soon to know if the approach works. Side effects are possible, and the combination therapies may not be safe or effective.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.